Suppr超能文献

EGR3 和雌酮参与了乳腺癌的他莫昔芬耐药和进展。

EGR3 and estrone are involved in the tamoxifen resistance and progression of breast cancer.

机构信息

School of Medicine, Nankai University, Tianjin, 300071, China.

State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin, 300350, China.

出版信息

J Cancer Res Clin Oncol. 2023 Dec;149(20):18103-18117. doi: 10.1007/s00432-023-05503-6. Epub 2023 Nov 24.

Abstract

BACKGROUND

Tamoxifen (Tam) is an effective treatment for estrogen receptor (ER) positive breast cancer. However, a significant proportion of patients develop resistance under treatment, presenting a therapeutic challenge. The study aims to determine the role of early growth response protein (EGR) 3 in tamoxifen resistance (TamR) and elucidate its molecular mechanism.

METHODS

TamR cell models were established and NGS was used to screening signaling alternation. Western blot and qRT-PCR were used to analysis the expression of ERα, EGR3, MCL1 and factors associated with apoptosis. CCK8, colony formation and apoptosis assay were used to analysis resistance to Tam. Immunofluorescence, chromatin immunoprecipitation, and dual luciferase assays were used to investigate mechanism of regulation.

RESULTS

We observed that EGR3, a deeply rooted ERα response factor, showed increased upregulation in response to both estrone (E1) and Tam in TamR cells with elevated level of E1 and ERα expression, indicating a potential connection between EGR3 and TamR. Mechanically, manipulating EGR3 expression revealed that it imparted resistance to Tam through increased expression of the downstream molecule MCL1 (apoptosis suppressor gene) that it regulated. Mechanismly, EGR3 directly binds to the promoter of the anti-apoptotic factor MCL1 gene, facilitating its transcription. Furthermore, apoptosis assays revealed that E1 reduces Tam induced apoptosis by upregulating EGR3 expression. Importantly, clinical public database confirmed the high expression of EGR3 in breast cancer tissue and in Tam-treated patients.

CONCLUSIONS

These findings shed light on the novel estrogen/EGR3/MCL1 axis and its role in inducing TamR in ER positive breast cancer. EGR3 emerges as a promising target to overcome TamR. The elucidation of this mechanism holds potential for the development of new therapeutic modalities to overcome endocrine therapy resistance in clinical settings.

摘要

背景

他莫昔芬(Tam)是治疗雌激素受体(ER)阳性乳腺癌的有效药物。然而,相当一部分患者在治疗过程中产生耐药性,这是一个治疗挑战。本研究旨在确定早期生长反应蛋白(EGR)3在他莫昔芬耐药(TamR)中的作用,并阐明其分子机制。

方法

建立 TamR 细胞模型,采用 NGS 筛选信号改变。Western blot 和 qRT-PCR 分析 ERα、EGR3、MCL1 和与凋亡相关的因素表达。CCK8、集落形成和凋亡实验分析 Tam 耐药性。免疫荧光、染色质免疫沉淀和双荧光素酶实验用于研究调控机制。

结果

我们观察到 EGR3 是一种根深蒂固的 ERα 反应因子,在 TamR 细胞中,无论是对雌酮(E1)还是 Tam 的反应,都表现出上调,同时伴有 E1 和 ERα 表达水平升高,表明 EGR3 与 TamR 之间存在潜在联系。通过操纵 EGR3 的表达,我们发现它通过调节下游分子 MCL1(凋亡抑制基因)的表达赋予 Tam 耐药性。机制上,EGR3 直接结合抗凋亡因子 MCL1 基因的启动子,促进其转录。此外,凋亡实验表明 E1 通过上调 EGR3 表达来减少 Tam 诱导的细胞凋亡。重要的是,临床公共数据库证实了 EGR3 在乳腺癌组织和 Tam 治疗患者中的高表达。

结论

这些发现揭示了新的雌激素/EGR3/MCL1 轴及其在诱导 ER 阳性乳腺癌 TamR 中的作用。EGR3 作为克服 TamR 的有前途的靶点出现。阐明这一机制为开发新的治疗方法以克服临床内分泌治疗耐药性提供了潜力。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验